To identify molecular modifiers in currently resistant cells that influence the sensitivity of BRAF mutant cells to TRAIL induced apoptosis, we recorded a panel of colon cancer cell lines to determine their response to the BRAF inhibitor PLX4720, which targets the mutated V600E form of BRAF. Here, BRAF is linked to malignant colon neoplasm.